BNB Plus Corp. is a diversified biotechnology and digital asset treasury company originally founded in 1983. It operates through three main segments: Therapeutic DNA Production Services, which focuses on enzymatic manufacturing of synthetic DNA for nucleic acid-based therapeutics; MDx Testing Services, offering clinical molecular diagnostic and genetic testing solutions; and DNA Tagging and Security Products and Services, which provide authentication and provenance verification through proprietary molecular tagging technologies. The company has recently rebranded from Applied DNA Sciences to BNB Plus Corp., reflecting a new strategic initiative centered on building an actively managed digital asset treasury with a focus on BNB (Binance Coin) exposure and yield generation through the Binance ecosystem. With institutional-grade digital asset management linked to blockchain and DeFi innovations, BNB Plus Corp. aims to blend biopharmaceutical technologies with emerging crypto-asset strategies, positioning itself at the intersection of life sciences and digital finance.